☆ 4.5 Letter

Secukinumab: a potential safe option in psoriasis patients affected by multiple sclerosis?

INTERNATIONAL JOURNAL OF DERMATOLOGY (2020)

期刊

INTERNATIONAL JOURNAL OF DERMATOLOGY

卷 59, 期 8, 页码 E308-E309

出版社

WILEY

DOI: 10.1111/ijd.14902

关键词

-

类别

Dermatology

向作者/读者索取更多资源

Protocol

Reagent

作者

我是这篇论文的作者

点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5

评分不足

次要评分

新颖性

-

重要性

-

科学严谨性

-

评价这篇论文

推荐

Article Biochemistry & Molecular Biology

Safe and Efficient Sigma1 Ligand: A Potential Drug Candidate for Multiple Sclerosis

Benedicte Oxombre, Fahima Madouri, Anne-Sophie Journe, Severine Ravez, Eloise Woitrain, Pascal Odou, Nathalie Duhal, Sandro Ninni, David Montaigne, Nadira Delhem, Patrick Vermersch, Patricia Melnyk

Summary: Multiple sclerosis (MS) is an autoimmune demyelinating and neurodegenerative disease of the central nervous system. Current management strategies have limitations in addressing the neurodegenerative process. This study identified the sigma1 (S1R) ligand-regulated chaperone as a promising target and found that oral administration of a specific compound reduced clinical progression in an MS experimental model.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

添加到收藏夹

Article Biochemistry & Molecular Biology

Metabolomic Changes in Patients Affected by Multiple Sclerosis and Treated with Fingolimod

Federica Murgia, Lorena Lorefice, Antonio Noto, Martina Spada, Jessica Frau, Giuseppe Fenu, Giancarlo Coghe, Antonella Gagliano, Luigi Atzori, Eleonora Cocco

Summary: Current treatment for Multiple Sclerosis (MS) involves multidisciplinary approach and disease-modifying therapies. Metabolomics is used to identify biomarkers/predictors of treatment response. This study evaluated metabolic changes in MS patients starting Fingolimod treatment, finding specific metabolomic features that predict therapeutic response and potential side effects. The results showed that Fingolimod influences aminoacidic and energy metabolisms and reduces oxidative stress and immune system activity, characteristic of MS.

METABOLITES (2023)

添加到收藏夹

Article Clinical Neurology

Transcranial magnetic resonance-guided focused ultrasound thalamotomy as a safe treatment option in multiple sclerosis patients with essential tremor

Cesare Gagliardo, Paolo Ragonese, Gerardo Domenico Iacopino, Giuseppe Salemi, Massimo Midiri, Marco D'Amelio

Summary: Transcranial magnetic resonance-guided focused ultrasound is a non-invasive treatment option for controlling tremors, with potential effectiveness for essential tremor in patients with multiple sclerosis. In two reported cases of patients with multiple sclerosis, this technique showed promise in controlling tremors without evidence of disease progression.

NEUROLOGICAL SCIENCES (2021)

添加到收藏夹

Article Neurosciences

Adiponectin in Cerebrospinal Fluid from Patients Affected by Multiple Sclerosis Is Correlated with the Progression and Severity of Disease

Signoriello Elisabetta, Mallardo Marta, Nigro Ersilia, Polito Rita, Casertano Sara, Di Pietro Andrea, Coletta Marcella, Monaco Maria Ludovica, Rossi Fabiana, Lus Giacomo, Daniele Aurora

Summary: Adiponectin levels in the cerebrospinal fluid were significantly elevated in multiple sclerosis (MS) patients and positively correlated with CSF IgG levels, suggesting a potential relationship with disease severity and prognosis. Changes in the oligomerization profile of adiponectin in CSF from MS patients, with increased high molecular weight and medium molecular weight forms, were also observed.

MOLECULAR NEUROBIOLOGY (2021)

添加到收藏夹

Article Medicine, General & Internal

Interleukin-17A-Correlated Myocarditis in Patients with Psoriasis: Cardiac Recovery following Secukinumab Administration

Andrea Frustaci, Nicola Galea, Lorenzo Dominici, Romina Verardo, Maria Alfarano, Rossella Scialla, Antonio Giovanni Richetta

Summary: This study reports 5 cases of psoriasis-related myocarditis and suggests that IL-17A-related myocarditis may occur in up to 5% of psoriasis patients.

JOURNAL OF CLINICAL MEDICINE (2023)

添加到收藏夹

Review Medicine, Research & Experimental

Therapeutic potential of mesenchymal stem cells in multiple organs affected by COVID-19

Gustavo C. Paris, Aline A. Azevedo, Adriana L. Ferreira, Yanca M. A. Azevedo, Mateus A. Rainho, Genilza P. Oliveira, Karina R. Silva, Erika A. C. Cortez, Ana C. Stumbo, Simone N. Carvalho, Lais de Carvalho, Alessandra A. Thole

Summary: This article discusses the impact of the novel coronavirus on the lungs, kidneys, heart, vasculature, and central nervous system, as well as the therapeutic mechanisms of MSC in each tissue. Additionally, it explores the therapeutic effects of MSC in high-risk groups for COVID-19, such as obese, diabetic, and hypertensive patients.

LIFE SCIENCES (2021)

添加到收藏夹

Review Biochemistry & Molecular Biology

Current Immunological and Clinical Perspective on Vaccinations in Multiple Sclerosis Patients: Are They Safe after All?

Shani Witman Tsur, Eli Adrian Zaher, Meydan Tsur, Karolina Kania, Alicja Kalinowska-Lyszczarz

Summary: Vaccines stimulate the immune system to protect against specific pathogens, and there is currently no evidence to suggest that various vaccines increase the risk for multiple sclerosis patients. Further research is needed to explore the potential protective implications of certain vaccines in MS patients.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

添加到收藏夹

Review Clinical Neurology

How is neuromuscular fatigability affected by perceived fatigue and disability in people with multiple sclerosis?

Nicolas Royer, Kyla Coates, Saied Jalal Aboodarda, Jean-Philippe Camdessanche, Guillaume Y. Millet

Summary: Fatigue is a common complaint of patients with multiple sclerosis, but its cause and the relationship between resistance to fatigability, disability level, and neuromuscular performance are not well understood. This review examines the effects of multiple sclerosis on corticospinal and muscular mechanisms of muscle contraction and their potential influence by disability level and fatigue. It suggests that impaired neuromuscular function during exercise is more pronounced with increased disability, and fatigue level is linked to resistance to fatigability, but not to rest-related neuromuscular function. Further research is needed to better understand the impact of fatigue and disability on fatigability, particularly at the corticospinal level.

FRONTIERS IN NEUROLOGY (2022)

添加到收藏夹

Article Pharmacology & Pharmacy

Innovative Pediatric Development for Secukinumab in Psoriasis: Faster Patient Access, Reduction of Patients on Control

Ruquan You, Sebastian Weber, Bruno Bieth, Marc Vandemeulebroecke

Summary: This paper describes the innovative pediatric development strategy of secukinumab in psoriasis. By leveraging experience and regulatory openness to innovative quantitative approaches, the pediatric development of secukinumab was substantially accelerated.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2022)

添加到收藏夹

Article Medicine, General & Internal

Effects of secukinumab and adalimumab on serum uric acid level in patients with plaque psoriasis

Zheng Zhao, Lin Cai, Si Zhang, Heng Zhang, Xiaoyang Liu, Chenglong Li, Yan Zhao, Jianzhong Zhang

Summary: This study found that patients with psoriasis have higher serum uric acid levels and a higher prevalence of hyperuricemia compared to healthy controls. Treatment with secukinumab successfully decreased serum uric acid levels in patients with psoriasis, while adalimumab had no significant effect on serum uric acid levels.

CHINESE MEDICAL JOURNAL (2022)

添加到收藏夹

Article Multidisciplinary Sciences

Global circRNA expression changes predate clinical and histological improvements of psoriasis patients upon secukinumab treatment

Sabine Seeler, Liviu-Ionut Moldovan, Trine Bertelsen, Henrik Hager, Lars Iversen, Claus Johansen, Jorgen Kjems, Lasse Sommer Kristensen

Summary: Psoriasis is a common chronic inflammatory skin disease. The dynamics of non-coding RNA expression during treatment can provide insights into the disease mechanism and treatment effectiveness.

PLOS ONE (2022)

添加到收藏夹

Article Immunology

Case Report: Rapid Desensitization to Ocrelizumab for Multiple Sclerosis Is Effective and Safe

Marcelo Vivolo Aun, Fernando Freua, Victor Hugo Rocha Marussi, Pedro Giavina-Bianchi

Summary: Ocrelizumab, a monoclonal antibody used in the treatment of multiple sclerosis, can cause immediate hypersensitivity reactions in some patients. We present a case report of successful desensitization therapy in a patient who experienced such a reaction, allowing for continued treatment. Desensitization should be considered a safe option for patients with immediate hypersensitivity reactions to Ocrelizumab.

FRONTIERS IN IMMUNOLOGY (2022)

添加到收藏夹

Article Dermatology

Secukinumab is effective and safe in the long-term treatment of plaque psoriasis in a daily practice setting: Multicenter study in 384 Spanish patients

Pablo Chicharro, Mar Llamas-Velasco, Susana Armesto, Enrique Herrera Acosta, David Vidal, Eva Vilarrasa, Raquel Rivera-Diaz, Pablo De-la-Cueva, Antonio Martorell-Calatayud, Ferran Ballesca, Isabel Belinchon, Gregorio Carretero, Lourdes Rodriguez, Alberto Romero-Mate, Josep Pujol-Montcusi, Laura Salgado, Antonio Sahuquillo-Torralba, Pablo Coto-Segura, Ofelia Baniandres Rodriguez, Rosa Feltes, Jose Riera-Monroig, Esteban Dauden

Summary: The study assessed the long-term effectiveness and safety of secukinumab in Spanish patients with moderate-to-severe psoriasis in a daily practice setting, finding that the drug was particularly effective for patients with high PSI and had good long-term safety in routine clinical practice.

DERMATOLOGIC THERAPY (2022)

添加到收藏夹

Article Pharmacology & Pharmacy

Safety evaluation of secukinumab in pediatric patients with plaque psoriasis

Klaudia Bardowska, Piotr K. Krajewski, Jacek C. Szepietowski

Summary: This article provides an extensive review of the safety and efficiency of secukinumab in the treatment of plaque psoriasis in the pediatric population. The available data suggest that secukinumab may be a promising therapy for children with moderate to severe psoriasis, with a favorable safety profile and sustained efficiency in improving quality of life.

EXPERT OPINION ON DRUG SAFETY (2022)

添加到收藏夹

Article Clinical Neurology

Ketogenic diet may improve sleep quality and daytime somnolence in patients affected by multiple sclerosis. Results of an exploratory study

Giovanni Merlino, Riccardo Garbo, Simone Dal Bello, Ilaria Del Negro, Eleonora Lamon, Francesca Filippi, Andrea Bernardini, Simone Lorenzut, Laura Ceccarelli, Arianna Cella, Alessandro Mar, Yan Tereshko, Gian Luigi Gigli, Mariarosaria Valente

Summary: This study found that the ketogenic diet (KD) may improve sleep complaints in patients with multiple sclerosis (MS) and have a positive impact on their psychological status and quality of life (QoL) through improving sleep quality.

SLEEP MEDICINE (2023)

添加到收藏夹

Letter Dermatology

A case of psoriatic alopecia secondary to certolizumab pegol: clinical and trichoscopic evaluation

Wanda Lauro, Vincenzo Picone, Luisa Abategiovanni, Maria Vastarella, Lucia Gallo, Gabriella Fabbrocini, Matteo Megna

INTERNATIONAL JOURNAL OF DERMATOLOGY (2023)

添加到收藏夹

Letter Dermatology

A case of psoriasis and multiple sclerosis succesfully treated with concomitant fingolimod and secukinumab

Matteo Megna, Matteo Noto, Gabriella Fabbrocini, Luigi Fornaro

AUSTRALASIAN JOURNAL OF DERMATOLOGY (2023)

添加到收藏夹

Review Pharmacology & Pharmacy

Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part I: focus on pediatric patients

Matteo Megna, Elisa Camela, Teresa Battista, Lucia Genco, Fabrizio Martora, Matteo Noto, Vincenzo Picone, Angelo Ruggiero, Giuseppe Monfrecola, Gabriella Fabbrocini, Luca Potestio

Summary: This article reviews the current literature on the use of biologic drugs and oral small molecules (OSM) for the treatment of pediatric psoriasis and concludes that they are an ideal treatment option with excellent efficacy and safety profiles compared to traditional systemic drugs.

EXPERT OPINION ON DRUG SAFETY (2023)

添加到收藏夹

Review Pharmacology & Pharmacy

Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part II: focus on elderly patients

Matteo Megna, Elisa Camela, Teresa Battista, Lucia Genco, Fabrizio Martora, Matteo Noto, Vincenzo Picone, Angelo Ruggiero, Giuseppe Monfrecola, Gabriella Fabbrocini, Luca Potestio

Summary: The management of moderate-to-severe forms of psoriasis in elderly patients is a frequent concern due to the higher risk of adverse events, logistic issues, and comorbidities. Traditional systemic treatments are often contraindicated, making biologic drugs and small molecules a valuable option. However, data on their effectiveness and safety in elderly patients are limited.

EXPERT OPINION ON DRUG SAFETY (2023)

添加到收藏夹

Letter Dermatology

A case of erythrodermic psoriasis rapidly and successfully treated with Bimekizumab

Matteo Megna, Teresa Battista, Luca Potestio, Angelo Ruggiero, Virginia Ventura, Gabriella Fabbrocini, Vincenzo Picone

JOURNAL OF COSMETIC DERMATOLOGY (2023)

添加到收藏夹

Letter Dermatology

Comment on 'Associations between hidradenitis suppurativa and dermatological conditions in adults: a national cross-sectional study'

Fabrizio Martora, Angelo Ruggiero, Teresa Battista, Luca Potestio, Matteo Megna

CLINICAL AND EXPERIMENTAL DERMATOLOGY (2023)

添加到收藏夹

Letter Dermatology

Comment on 'Oral ivermectin to treat scabies: a comparison of two different regimens'

Luca Potestio, Angelo Ruggiero, Gabriella Fabbrocini, Fabrizio Martora, Luca Costanzo, Lucia Gallo

Summary: Current guidelines recommend oral ivermectin as the first-line treatment, with a dose of 200 μg/kg taken in two doses 1-week apart (to be taken with food). However, the recently approved ivermectin formulation in Italy suggests a single dose. In response to this, we conducted a retrospective analysis at our Dermatological Clinic of Mycology and Parasitosis and present our findings, following a similar study conducted by Balestri et al.

CLINICAL AND EXPERIMENTAL DERMATOLOGY (2023)

添加到收藏夹

Article Pharmacology & Pharmacy

Efficacy and safety of sonidegib for the management of basal cell carcinoma: a drug safety evaluation

Alessia Villani, Massimiliano Scalvenzi, Giuseppe Micali, Francesco Lacarrubba, Lucia Genco, Angelo Ruggiero, Luigi Fornaro, Gianluca Guerrasio, Luca Potestio

Summary: Surgery is the standard treatment for most basal cell carcinomas (BCC), but in some cases, radiotherapy, ablative and topical treatments may also be valuable options. Locally advanced BCCs (laBCC) and metastatic BCC, also referred to as 'difficult-to-treat' BCC, pose a challenge for current treatment approaches. The development of new selective therapies targeting the Hedgehog (HH) pathway, such as sonidegib, has shown promising results in managing difficult-to-treat BCC.

EXPERT OPINION ON DRUG SAFETY (2023)

添加到收藏夹

Article Pharmacology & Pharmacy

Bimekizumab treatment in patients with moderate to severe plaque psoriasis: a drug safety evaluation

Angelo Ruggiero, Luca Potestio, Fabrizio Martora, Alessia Villani, Rosita Comune, Matteo Megna

Summary: Biological treatments have revolutionized the management of moderate-to-severe psoriasis, and bimekizumab, a novel IL-17 inhibitor, shows unique efficacy and safety profiles compared to other biologics. This review evaluates the safety of bimekizumab in treating moderate-to-severe plaque psoriasis and highlights its superior efficacy compared to other biological classes.

EXPERT OPINION ON DRUG SAFETY (2023)

添加到收藏夹

Article Dermatology

Tildrakizumab for the Treatment of Moderate-to-Severe Psoriasis: Results from 52 Weeks Real-Life Retrospective Study

Angelo Ruggiero, Gabriella Fabbrocicni, Sara Cacciapuoti, Luca Potestio, Lucia Gallo, Matteo Megna

Summary: Background: Tildrakizumab has shown promising efficacy and safety in clinical trials, but real-life data are limited. Objective: To assess the efficacy and safety of tildrakizumab in patients with moderate-to-severe psoriasis. Results: The study showed significant reduction in PASI score and high rates of PASI90 and PASI100 responses, with few reported adverse events, up to 52 weeks of follow-up. Treatment also improved patients' quality of life.

CLINICAL COSMETIC AND INVESTIGATIONAL DERMATOLOGY (2023)

添加到收藏夹

Article Dermatology

Injections Site Reactions and Biologics for Psoriasis: A Questionnaire Based Real Life Study

Matteo Megna, Teresa Battista, Matteo Noto, Vincenzo Picone, Gabriella Fabbrocini, Angelo Ruggiero, Lucia Genco

Summary: This study found that a considerable proportion of psoriasis patients who received biologic treatment experienced injection site reactions (ISRs) such as swelling, pain, burning, and erythema, which could affect patient adherence. The incidence of these symptoms varied among different classes of biologics, with Ixekizumab showing the highest rates. However, these ISRs did not lead to discontinuation or delay of treatment.

CLINICAL COSMETIC AND INVESTIGATIONAL DERMATOLOGY (2023)

添加到收藏夹

Review Biochemistry & Molecular Biology

New Onset and Exacerbation of Psoriasis Following COVID-19 Vaccination: A Review of the Current Knowledge

Luca Potestio, Teresa Battista, Sara Cacciapuoti, Angelo Ruggiero, Fabrizio Martora, Luigi Fornaro, Elisa Camela, Matteo Megna

Summary: COVID-19 vaccination is crucial in overcoming the pandemic, but it may cause mild to moderate adverse events, including cutaneous reactions such as psoriasis exacerbation or new-onset psoriasis. This manuscript aims to review the literature and explore the possible pathogenetic mechanisms of post-vaccination psoriasis exacerbations and new-onset psoriasis.

BIOMEDICINES (2023)

添加到收藏夹

Review Dermatology

Use of Biological Therapies for the Management of Pustular Psoriasis: A New Era?

Matteo Megna, Elisa Camela, Angelo Ruggiero, Teresa Battista, Fabrizio Martora, Sara Cacciapuoti, Luca Potestio

Summary: Generalized pustular psoriasis (GPP) is a severe form of psoriasis characterized by recurring episodes of widespread erythema with pustules. The pathology of GPP involves irregular innate and adaptive immune responses, with the IL36 pathway being implicated. Conventional systemic drugs used for plaque psoriasis are commonly employed as the first-line treatment for GPP, but biologic drugs show promise as an alternative option. The recent approval of spesolimab, an anti-IL36 receptor monoclonal antibody, for GPP highlights the potential of biologic therapies in GPP treatment.

CLINICAL COSMETIC AND INVESTIGATIONAL DERMATOLOGY (2023)

添加到收藏夹

Review Dermatology

Biologics for the Management of Erythrodermic Psoriasis: An Updated Review

Luca Potestio, Elisa Camela, Sara Cacciapuoti, Luigi Fornaro, Angelo Ruggiero, Fabrizio Martora, Teresa Battista, Matteo Megna

Summary: Erythrodermic psoriasis is a severe and rare variant of psoriasis characterized by generalized scaling and erythema. It can have systemic symptoms and can be life-threatening if not treated properly. Conventional systemic drugs often have contraindications and limited efficacy and safety, while biologic drugs have shown potential but are still off-label for erythrodermic psoriasis. Our study aims to provide a comprehensive perspective on the use of biologic drugs for the management of erythrodermic psoriasis.

CLINICAL COSMETIC AND INVESTIGATIONAL DERMATOLOGY (2023)

添加到收藏夹

Article Medicine, General & Internal

Long-Term Efficacy and Safety of Risankizumab for Moderate to Severe Psoriasis: A 2-Year Real-Life Retrospective Study

Matteo Megna, Angelo Ruggiero, Teresa Battista, Laura Marano, Sara Cacciapuoti, Luca Potestio

Summary: This study investigated the long-term efficacy and safety of risankizumab for the management of moderate to severe psoriasis. The results showed significant reduction in psoriasis severity scores from week 16 and maintained up to week 104, with no serious adverse events reported.

JOURNAL OF CLINICAL MEDICINE (2023)

添加到收藏夹

暂无数据

© Peeref 2019-2024. All rights reserved.